Mechanism of Action
An investigational monoclonal antibody targeting BDCA2, a receptor found specifically on plasmacytoid dendritic cells — the immune cells primarily responsible for producing type I interferon in SLE. By binding BDCA2, litifilimab suppresses interferon and other inflammatory mediator production at its cellular source, upstream of where anifrolumab acts. Being evaluated in two ongoing Phase 3 trials for SLE, with topline results anticipated by the end of 2026; already holds FDA Breakthrough Therapy Designation for cutaneous lupus (skin-limited disease).